Skip to main content
22/12/2023

Work Led by Vall d'Hebron recognized in Third Edition of Esperanza Nacional Award for Research in Multiple Sclerosi

Premio Nacional Esperanza a la Investigación en EM

22/12/2023

Dr. Carmen Espejo and Dr. Georgina Arrambide, researchers at Cemcat and Vall d'Hebron Research Institute, are the first authors of the article.

The Esperanza Nacional Award for Research in Multiple Sclerosis granted by the Multiple Sclerosis Association of Toledo (ADEMTO) aims to promote and recognize the research carried out by national research groups in the field of multiple sclerosis. This year, the third edition of the award has recognized a work led by researchers from Cemcat, Vall d'Hebron University Hospital and Vall d'Hebron Research Institute (VHIR).

The study, published in 2022 in the journal Brain, analyzes the levels of free kappa light chains in cerebrospinal fluid and concludes that their accuracy in diagnosing new cases of multiple sclerosis is slightly higher than that of oligoclonal bands, the biomarker currently included in the diagnostic criteria for the disease. "Both types of proteins are associated with inflammatory processes", explains Dr. Carmen Espejo, principal investigator at Cemcat and the Clinical Neuroimmunology group at VHIR, and first author of the study, together with Dr. Georgina Arrambide, neurologist and researcher at Cemcat and the Clinical Neuroimmunology group at VHIR.

"Our results show that determining the kappa free light chain index is a fast, cost-effective and readily available alternative when it is not possible to assess the presence of oligoclonal bands," the researcher says. "Therefore, we propose to modify the current diagnostic criteria, the McDonald 2017 criteria, so that either biomarker can be used to diagnose the disease."

Dr. Espejo collected the award on Monday, December 18 at ADEMTO headquarters in Toledo. "We are very grateful, as the award is a recognition of our research and a motivation to continue advancing in the knowledge of multiple sclerosis."

The study has proven the efficacy of a new biomarker to diagnose MS

Related news

In total, different projects of six research groups will be promoted, focusing on precision medicine and advanced therapies.

The research findings propose to modify the McDonald 2017 criteria, only in those in whom diagnosis using the current criteria is not possible.

The meeting, held between November 29 and December 2 in Barcelona, brought together experts and opinion leaders in the field of multiple sclerosis from around the world.

Related professionals

Carmen Espejo Ruiz

Carmen Espejo Ruiz

Main researcher
Clinical Neuroimmunology
Read more
Silvia Ferrer López

Silvia Ferrer López

Administration and Management
Clinical Neuroimmunology
Read more
Carmen Tur Gomez

Carmen Tur Gomez

Main researcher
Clinical Neuroimmunology
Read more
Javier Domeño Baztán

Javier Domeño Baztán

Research technician
Clinical Neuroimmunology
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.